CTSO
Cytosorbents Corporation
CTSO's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over CTSO overall, supported by stronger fundamentals and lower modeled downside.
CTSO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
CTSO's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CTSO PE Valuation
CTSO has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CTSO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect CTSO's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CTSO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$5.80 | -$2.40 |
| Q1 2026 | -$3.80 | +$1.80 |
| Q4 2025 | -$2.60 | +$5.00 |
| Q3 2025 | -$3.60 | +$3.60 |
| Q2 2025 | -$3.40 | +$7.20 |
| Q1 2025 | -$5.60 | +$6.20 |
| Q4 2024 | -$7.60 | +$5.20 |
| Q3 2024 | -$7.20 | +$3.60 |
CTSO is still losing money, but far less than before: $5.80 per share over the past year, against $18.40 at its worst in late 2022.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CTSO on earnings quality, reporting a profit while its opponent remains loss making.
CTSO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $9.6M | +0.2% |
| Q1 2026 | $8.9M | +1.6% |
| Q4 2025 | $9.2M | +42% |
| Q3 2025 | $9.5M | +1% |
| Q2 2025 | $9.6M | -2.8% |
| Q1 2025 | $8.7M | -11% |
| Q4 2024 | $6.5M | -25% |
| Q3 2024 | $9.4M | +6.6% |
CTSO's revenue has grown year over year for four quarters in a row: $10M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -27% | +10 points |
| Q1 2026 | -34% | +10 points |
| Q4 2025 | -47% | +15 points |
| Q3 2025 | -30% | +17 points |
| Q2 2025 | -38% | -3 points |
| Q1 2025 | -45% | +5.8 points |
| Q4 2024 | -62% | +47 points |
| Q3 2024 | -47% | +37 points |
CTSO's operating margin was −27% last quarter, up 10 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CTSO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CTSO on profitability, with a higher operating margin.
CTSO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$597K | +$949.9K |
| Q1 2026 | -$1.2M | +$2.3M |
| Q3 2025 | -$2.6M | -$132.8K |
| Q2 2025 | -$1.5M | +$3.2M |
| Q1 2025 | -$3.5M | +$1.4M |
| Q3 2024 | -$2.5M | +$2.9M |
| Q2 2024 | -$4.8M | +$1.9M |
| Q1 2024 | -$4.9M | -$1.3M |
CTSO has burned cash in almost every quarter: −$9M over the past year, against −$12M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CTSO on cash generation, producing positive trailing cash flow while its opponent burns cash.
CTSO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +3.4K shares |
| 1 year | -6.5% | -218K shares |
| 3 years | +43% | +940K shares |
| 5 years | +45% | +974K shares |
| Available history | +94% | +1.5M shares |
CTSO has the edge over LLY on shareholder dilution, with a more favorable share count trend.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CTSO Net Leverage
CTSO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CTSO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.9 | Neutral |
| Stochastic | 31.3 | Neutral |
CTSO's weekly RSI is 40 (neutral) and its Stochastic is 31 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CTSO PE vs Healthcare Sector
CTSO has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CTSO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.54 | 18% above |
| 20 week MA | $6.09 | 12% below |
| 50 week MA | $9.78 | 45% below |
| 100 week MA | $14.6 | 63% below |
| 200 week MA | $25.4 | 79% below |
CTSO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 79% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CTSO on trend strength, trading above more of its moving averages.
CTSO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $76.6 | $166.2 | +117% |
| 2021 | $166.2 | $89.0 | -46% |
| 2022 | $89.0 | $28.0 | -69% |
| 2023 | $28.0 | $22.2 | -21% |
| 2024 | $22.2 | $18.8 | -15% |
| 2025 | $18.8 | $13.6 | -28% |
| 2026 YTD | $13.6 | $5.37 | -61% |
CTSO has finished five years in a row lower, and it's down 61% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CTSO on returns for 2026, with the stronger performance.